Best Practice & Research Clinical Haematology

(The median citation count of Best Practice & Research Clinical Haematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes70
Molecular markers in ALL: Clinical implications32
COVID-19 disease and immune dysregulation30
Immunologic effects on the haematopoietic stem cell in marrow failure23
The promise of macrophage directed checkpoint inhibitors in myeloid malignancies20
CD33 directed bispecific antibodies in acute myeloid leukemia18
Acute myeloid leukemia and artificial intelligence, algorithms and new scores17
Perspectives on current survival and new developments in AML17
Immune checkpoint inhibitors in acute myeloid leukemia17
Treatment of telomeropathies16
COVID-19 and antiphospholipid antibodies16
TCR gene-engineered cell therapy for solid tumors14
Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax14
CD123 bi-specific antibodies in development in AML: What do we know so far?13
Distinguishing constitutional from acquired bone marrow failure in the hematology clinic13
COVID-19 and HSCT (Hematopoietic stem cell transplant)12
Congenital amegakaryocytic thrombocytopenia – Not a single disease12
Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome12
New targets for CAR T therapy in hematologic malignancies11
Somatic mosaicism in inherited bone marrow failure syndromes10
Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage10
Blood coagulation and cancer genes10
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?10
Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia10
Have any strategies in Ph-like ALL been shown to be effective?10
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia10
Mechanisms of thrombosis in pancreatic ductal adenocarcinoma9
Toxicities associated with adoptive cellular therapies9
Thrombosis and bleeding in hematological malignancy9
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?8
GATA2 and marrow failure8
Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults8
Molecular genetics of MDS/MPN overlap syndromes7
Cytogenetics in the genomic era7
Clinical experience of CAR T cells for multiple myeloma7
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults7
Overcoming graft failure after haploidentical transplantation: Is this a possibility?7
WGS and WTS in leukaemia: A tool for diagnostics?7
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents7
Antibody based therapy in relapsed acute lymphoblastic leukemia6
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults6
Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?6
Clonal hematopoiesis and bone marrow failure syndromes6
CML - Not only BCR-ABL1 matters6
Vaccine-induced immune thrombotic thrombocytopenia6
Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?5
Accelerated and blast phase myeloproliferative neoplasms5
Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci5
Marrow failure and aging: The role of “Inflammaging”5
Dysregulation of Protein S in COVID-195
Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL)5
Challenges in anticoagulation for patients with brain tumors5
Coagulopathy in COVID-19 and anticoagulation clinical trials5
Spliceosomal factor mutations and mis-splicing in MDS5
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care5
Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?5
Advances in CAR design5
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma5
Myeloproliferative neoplasms in adolescents and young adults5
Bone marrow transplantation for acquired aplastic anemia: What's new5
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia4
Advances in polycythemia vera and lessons for acute leukemia4
A review of latest clinical practice guidelines for the management of cancer-associated thrombosis4
How old is too old for a transplant?4
It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS4
A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition3
Progress in the management of chronic GVHD insights into novel therapies to treat and manage GVHD lasting longer than 12 Months3
Founder and subclonal mutations in myelodysplastic syndromes and related myeloid neoplasms3
Changing trends in the therapy of acute myeloid leukemia3
Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome3
A perspective on the sickle cell disease international COVID-19 registry3
What are the molecular mechanisms driving the switch from MPNs to leukemia?3
Monoclonal antibodies in frontline acute lymphoblastic leukemia3
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma3
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia3
Which novel agents will have a clinically meaningful impact in AML at diagnosis?3
Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps3
Addressing symptom burden in myeloproliferative neoplasms3
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-193
Hypomethylating agents as maintenance therapy following allogeneic hematopoietic cell transplantation for myeloid malignancies2
Transplantation algorithm for myelofibrosis in 2022 and beyond2
Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant?2
Principles of cost-effectiveness studies and their use in haematology2
Molecular alterations governing predisposition to myelodysplastic syndromes: Insights from Shwachman-Diamond syndrome2
Challenges of diagnosing and managing pre-fibrotic myelofibrosis: A case-based and practical approach2
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms2
Thrombopoietin receptor agonists for marrow failure: A concise clinical review2
How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?2
Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma2
Cancer associated thrombosis in pediatric patients2
Is the current consolidation regimen for AML evidence-based?2
Graft versus Leukemia in 20232
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma2
Treatment modalities in cancer-associated venous thromboembolism (VTE)2
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program2
The role of randomized controlled trials, registries, observational databases in evaluating new interventions2
Financial toxicity in patients with leukemia undergoing hematopoietic stem cell transplantation: A systematic review2
What is relative survival and what is its role in haematology?2
The potential role of Bi-specific antibodies in acute myeloid leukemia2
CAR T in adult ALL: When and for whom?2
How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML1
Managing older adults with Ph-negative ALL: What is new? Recent advances in treating older adults with ALL1
Acute GVHD: New approaches to clinical trial monitoring1
Bone marrow failure syndromes1
Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults1
When will chemotherapy be replaced in upfront induction therapy for adult acute lymphoblastic leukemia (ALL)?1
Clinical experience of CAR T cell therapy in lymphomas1
How can we incorporate molecular data into the IPSS?1
Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders1
Improving clinical trials in higher-risk myelodysplastic syndromes1
Is there an optimal adjunct therapy to traditional cytotoxic induction?1
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies1
Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?1
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL1
Novel therapeutic targets for chronic myelomonocytic leukemia1
COVID-19 outcomes in sickle cell disease and sickle cell trait1
Redox stress in COVID-19: Implications for hematologic disorders1
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”1
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia1
Recent progress in acute leukemia and myelodysplasia1
Cytogenetics and molecular genetics of myelodysplastic neoplasms1
Diagnosis and management of cutaneous lymphomas and lymphoid proliferations in children, adolescents and young adults (CAYA)1
WHO, what, when, where, and why: New classification systems for acute myeloid leukemia and their impact on clinical practice1
Since everyone has a donor, why are some eligible patients still not transplanted?1
Contemporary and future strategies in polycythemia vera1
Will immunotherapy lead to a breakthrough in the treatment of older adults with ALL?1
Hodgkin lymphoma: Focus on evolving treatment paradigms1
What is the role of the bone marrow microenvironment in AML?1
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia1